Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaRx, a clinical-stage biopharmaceutical company, has appointed Norrie Russell as its new president and COO.
Subscribe to our email newsletter
Prior to NovaRx, Dr Russell was the president and CEO of Kalos Therapeutics, a biotechnology company focused on the development of cancer therapies. Before Kalos, Dr Russell served as chief scientific officer at Invitrogen.
Dr Russell has also served as president and CEO of Aviva Biosciences and Lynx Therapeutics. Dr Russell holds a PhD in physiology from Glasgow University, Scotland.
Habib Fakhrai, executive vice chairman of NovaRx and the company’s founding scientist, will assume the title of chief scientific officer.
Justin Murdock, CEO of NovaRx, said: “We are pleased to have Norrie joining the team. His energy, enthusiasm and experience will help drive NovaRx to new levels and accelerate our ability to get innovative new treatments to cancer patients.”